Revisiting the Role of p53 in Prostate Cancer

Miriam Teroerde, MD; Cathleen  Nientiedt, MD; Anette Duensing, MD; Markus Hohenfellner, MD; Albrecht Stenzinger, MD; Stefan Duensing, MD

doi:10.36255/exonpublications.prostatecancer.p53.2021

PDF HTML XML

Published: May 27, 2021

DOI: https://doi.org/10.36255/exonpublications.prostatecancer.p53.2021

Keywords:

castration-naïve prostate cancer, castration resistance prostate cancer, p53, therapy resistance, TP53

Miriam Teroerde, MD

Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany

Cathleen Nientiedt, MD

Department of Medical Oncology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), Im Neuenheimer Feld 460, D-69120 Heidelberg, Germany

Anette Duensing, MD

Department of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 420, D-69120 Heidelberg, Germany

Markus Hohenfellner, MD

Department of Urology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT) Heidelberg, Im Neuenheimer Feld 420, D-69120 Heidelberg, Germany

Albrecht Stenzinger, MD

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, D-69120, Heidelberg, Germany

Stefan Duensing, MD

Molecular Urooncology, Department of Urology, University Hospital Heidelberg, Im Neuenheimer Feld 517, D-69120 Heidelberg, Germany

ABSTRACT

Mutations in the tumor suppressor gene TP53 are among the most common genetic aberrations in cancer. In prostate cancer, the role of mutant TP53 remains incompletely understood. Initially, mutations in TP53 were considered late events during malignant progression and associated with metastatic dissemination and castration resistance. However, recent studies report an inactivation of TP53 at an unexpectedly high frequency in primary as well as metastatic castration-naïve prostate cancer. In this chapter, we discuss the biology of p53, the relevance of TP53 mutations for prostate cancer progression and therapy resistance, and its potential role as a marker to identify patients who require more intensified treatment.